[Horacort (new steroid aerosol preparation) for treatment of bronchial asthma and allergic rhinitis].
The efficacy and safety of Horacort in the treatment of patients with asthma and allergic rhinitis were assessed. The studies were carried out on the group of 47 patients, 32 with mild to moderate bronchial asthma and 15 patients suffering from allergic seasonal or perrenial rhinitis. The asthmatic patients after two weeks run-in period were treated with Horacort (2 puffs bd) during eight weeks. Following randomly selected 16 persons were treated with Pulmicort and other 16 persons took placebo. Patients suffering from allergic rhinitis after one week run-in period were treated with Horacort (2 puffs bd) during four weeks and following with placebo during a next month. The excellent and good clinical results were observed in above 75% patients with bronchial asthma and allergic rhinitis. We observed a decrease in symptoms score, bronchial hyperreactivity, fenoterol consumption, eosinophil number and increase in spirometric parameters. A tolerance of Horacort was very good, only two patients in asthma group had a hoarseness and one with rhinitis epistaxis during therapy.
Chyrek-Borowska
S
S
Kliniki Alergologii AM w Białymstoku.
Siergiejko
Z
Z
Południewska
B
B
D000328:Adult; D000336:Aerosols / Q000627:therapeutic use; D000368:Aged; D001249:Asthma / Q000188:drug therapy*; D001993:Bronchodilator Agents / Q000627:therapeutic use*; D019819:Budesonide; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011282:Pregnenediones / Q000627:therapeutic use*; D006255:Rhinitis, Allergic, Seasonal / Q000188:drug therapy*; D016896:Treatment Outcome
D000336:Aerosols; D001993:Bronchodilator Agents; D011282:Pregnenediones; D019819:Budesonide
Horacort (nowy preparat steroidowy w aerozolu) w leczeniu astmy oskrzelowej i alergicznego niezytu nosa.